Author: Çınar, Olgu Erkin; Sayınalp, Başak; Karakulak, Elifcan Aladağ; Karataş, Ayşe Avşar; Velet, Mustafa; İnkaya, Ahmet Çağkan; Ersoy Ortaç, Nazmiye Ebru; Öcal, Serpil; Aksu, Salih; Haznedaroğlu, İbrahim Celalettin; Sayınalp, Nilgün; Özcebe, Osman İlhami
Title: CONVALESCENT (IMMUNE) PLASMA TREATMENT IN A MYELODYSPLASTIC COVID-19 PATIENT WITH DISSEMINATED TUBERCULOSIS Cord-id: vb88xlkm Document date: 2020_5_29
ID: vb88xlkm
Snippet: Abstract During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our exp
Document: Abstract During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our experience of multi-task treatment approach with convalescent immune plasma and anti-cytokine drug combination in a COVID-19 patient with extremely challenging comorbidities including active myeloid malignancy, disseminated tuberculosis and kidney failure.
Search related documents:
Co phrase search for related documents- absolute lymphocyte count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- absolute lymphocyte count and macrophage activation: 1
- absolute lymphocyte count and macrophage activation syndrome: 1
- acute phase and administration schedule: 1
- acute phase and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute phase and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute phase and macrophage activation syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute phase reaction and lymphocyte count: 1
- admission follow day and lymphocyte count: 1
- lymphocyte count and macrophage activation: 1, 2, 3, 4, 5, 6
- lymphocyte count and macrophage activation syndrome: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date